Business
Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing. The proceeds will advance its lead preclinical oncology programs to Phase I clinical studies and accelerate development of Pinetree's AbReptor™ platform. Participating investors include existing investors DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atin
About this update from Atinum Investment Co., Ltd
[{"type":"text","content":"CAMBRIDGE, Mass., Oct. 28, 2025 /PRNewswire/ -- Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing. The proceeds will advance its lead preclinical oncology programs to Phase I clinical studies and accelerate development of Pinetree's AbReptor™ platform. Participating investors include existing investors DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atinum Investment, S&S Investment, SJ Investment Partners, Smilegate Investment, and Gauss Capital Management, as well as new investors Korea Investment Partners and SV Investment.","length":732,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Pinetree Therapeutics) (PRNewsfoto/PineTree Therapeutics)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Pinetree Therapeutics) (PRNewsfoto/PineTree Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":122,"url":"https://media.zenfs.com/en/prnewswire.com/aff2f22d3154d7af4c0a10f7225dba76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I._hoNc5t2oNcIVtrN5knQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/aff2f22d3154d7af4c0a10f7225dba76","width":400,"height":122}},"href":"https://mma.prnewswire.com/media/1833787/PineTree_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Founded in 2019, Pinetree is an industry leader in the targeted protein degradation (TPD) field, developing a novel class of modular bispecific and multispecific protein degraders designed to selectively eliminate disease-driving membrane-bound and extracellular proteins. The AbReptor™ platform has demonstrated compelling preclinical efficacy and safety in degrading receptor tyrosine kinases (RTKs) that drive tumor growth and resistance, including targets refractory to existing tyrosine kinase inhibitors (TKIs) and immune checkpoint therapies.","length":549,"tagName":"p"},{"type":"text","content":""The AbReptor™ platform has repeatedly demonstrated durable activity across a broad range of RTK targets, including models resistant to standard-of-care therapies, and has unlocked the potential to develop a novel class of degrading antibody ...